Doses - VINBLASTINE SULFATE

For more information, refer to the Protocols found in the appendix, including: Handbookof Small Animal Practice (Stann 1988b).

Dogs:

For susceptible neoplastic diseases:
a) 2 mg/m2 IV every 7-14 days. (O'Keefe and Harris 1990), (Thompson 1989a)
b) 3 mg/m2 weekly, or 0.1 - 0.4 mg/kg weekly. (Macy 1986)
Note: According to reference by O'Keefe and Harris (above), 0.2 mg/kg can be a lethaldose in the dog. Until the safety of doses above 0.2 mg/kg can be verified, it issuggested to use the mg/m2 method of figuring the dose.
c) For lymphoma and mastocytoma: 2 mg/m2 weekly.
d) For lymphosarcoma and various carcinomas: 2.5 mg/m2 IV weekly. (MacEwen and Rosenthal 1989), (Rosenthal 1985)
e) 2 mg/m2 slow IV every 7-14 days. (Golden and Langston 1988)

Cats:

For susceptible neoplastic diseases:
a) For lymphosarcoma and mast cel neoplasms: 2 mg/m2 IV every 7-14 days. (Couto1989b)
b) 2 mg/m2 slow IV every 7-14 days. (Golden and Langston 1988)
Monitoring Parameters -

1.Efficacy

2.Toxicity
a) Complete blood counts with platelets
b) Liver function tests prior to therapy and repeated prn
c) Serum uric acid
Client Information - Clients must be briefed on the possibilities of severe toxicity developingfrom this drug, including drug-related mortality. Clients should contact the veterinarian should thepatient exhibit any symptoms of profound depression, abnormal bleeding (including bloodydiarrhea) and/or bruising.
Dosage Forms/Preparations/FDA Approval Status/Withholding Times - Veterinary-Approved Products: None

Human-Approved Products:

Vinblastine Sulfate for Injection 1 mg/ml in 10 ml & 25 ml vials; Velban® (Lilly) (Rx); generic;(Rx)
Vinblastine Powder for Injection 10 mg/vial. Generic (LyphoMed), (Quad) (Rx)